Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine

Xuan Qiu, Yuanxin Liang, Rani S. Sellers, Roman Perez-Soler, Yiyu Zou

Research output: Contribution to journalArticle

Abstract

Background Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. Methods Extrusion-precipitation method and DNA methyltransferase inhibition rate were used to measure the aerodynamic size and aerosolized Aza activity. In the single dose pharmacokinetic study, Aza concentrations in peripheral blood and lungs were measured by LC-MS method. In the multiple-dose toxicity studies, histo-pathological evaluation was used to determine the organ and bone marrow toxicities. Results In pharmacokinetic study, aerosolized Aza was found to deposit mainly into the lung with very little drug detected in the circulation. In contrast, intravenously injected (IV) Aza resulted in a high Aza concentration in the peripheral blood, with trace amounts of drug in the lung, and it was associated with significant myelosuppression. No significant myelosuppression, pulmonary toxicity, hepatotoxicity, or nephrotoxicity were observed at a daily dose of 2.5 mg/m2 for 7 days. Reversible lung inflammation was found in mice treated with 7.5 mg/m2 aerosolized Aza at 3 but not 6 weeks after treatment. Conclusions Aerosol Aza aerodynamic size favors deposition of the drug to the human lower airways. The aerosol process do not compromise the drug activity. Aerosolized Aza has higher lung deposition and much less systemic toxicity than IV drug. The safe starting dose for clinical phase I trials should be 2.5 mg/m2 for 5 to 7 days.

Original languageEnglish (US)
Pages (from-to)214-222e1
JournalClinical Lung Cancer
Volume17
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

Azacitidine
Pharmacokinetics
Lung
Aerosols
Pharmaceutical Preparations
Clinical Studies
Clinical Trials, Phase I
Methyltransferases
Epigenomics
Lung Neoplasms
Pneumonia
Bone Marrow

Keywords

  • Circulation drug levels
  • Demethylating agent
  • Inhalation
  • Lung deposition
  • Pulmonary and bone marrow toxicities

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine. / Qiu, Xuan; Liang, Yuanxin; Sellers, Rani S.; Perez-Soler, Roman; Zou, Yiyu.

In: Clinical Lung Cancer, Vol. 17, No. 3, 01.05.2016, p. 214-222e1.

Research output: Contribution to journalArticle

Qiu, Xuan ; Liang, Yuanxin ; Sellers, Rani S. ; Perez-Soler, Roman ; Zou, Yiyu. / Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine. In: Clinical Lung Cancer. 2016 ; Vol. 17, No. 3. pp. 214-222e1.
@article{cb5396ea28eb46d3ad5dab8e9abd4fc9,
title = "Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine",
abstract = "Background Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. Methods Extrusion-precipitation method and DNA methyltransferase inhibition rate were used to measure the aerodynamic size and aerosolized Aza activity. In the single dose pharmacokinetic study, Aza concentrations in peripheral blood and lungs were measured by LC-MS method. In the multiple-dose toxicity studies, histo-pathological evaluation was used to determine the organ and bone marrow toxicities. Results In pharmacokinetic study, aerosolized Aza was found to deposit mainly into the lung with very little drug detected in the circulation. In contrast, intravenously injected (IV) Aza resulted in a high Aza concentration in the peripheral blood, with trace amounts of drug in the lung, and it was associated with significant myelosuppression. No significant myelosuppression, pulmonary toxicity, hepatotoxicity, or nephrotoxicity were observed at a daily dose of 2.5 mg/m2 for 7 days. Reversible lung inflammation was found in mice treated with 7.5 mg/m2 aerosolized Aza at 3 but not 6 weeks after treatment. Conclusions Aerosol Aza aerodynamic size favors deposition of the drug to the human lower airways. The aerosol process do not compromise the drug activity. Aerosolized Aza has higher lung deposition and much less systemic toxicity than IV drug. The safe starting dose for clinical phase I trials should be 2.5 mg/m2 for 5 to 7 days.",
keywords = "Circulation drug levels, Demethylating agent, Inhalation, Lung deposition, Pulmonary and bone marrow toxicities",
author = "Xuan Qiu and Yuanxin Liang and Sellers, {Rani S.} and Roman Perez-Soler and Yiyu Zou",
year = "2016",
month = "5",
day = "1",
doi = "10.1016/j.cllc.2015.09.005",
language = "English (US)",
volume = "17",
pages = "214--222e1",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine

AU - Qiu, Xuan

AU - Liang, Yuanxin

AU - Sellers, Rani S.

AU - Perez-Soler, Roman

AU - Zou, Yiyu

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Background Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. Methods Extrusion-precipitation method and DNA methyltransferase inhibition rate were used to measure the aerodynamic size and aerosolized Aza activity. In the single dose pharmacokinetic study, Aza concentrations in peripheral blood and lungs were measured by LC-MS method. In the multiple-dose toxicity studies, histo-pathological evaluation was used to determine the organ and bone marrow toxicities. Results In pharmacokinetic study, aerosolized Aza was found to deposit mainly into the lung with very little drug detected in the circulation. In contrast, intravenously injected (IV) Aza resulted in a high Aza concentration in the peripheral blood, with trace amounts of drug in the lung, and it was associated with significant myelosuppression. No significant myelosuppression, pulmonary toxicity, hepatotoxicity, or nephrotoxicity were observed at a daily dose of 2.5 mg/m2 for 7 days. Reversible lung inflammation was found in mice treated with 7.5 mg/m2 aerosolized Aza at 3 but not 6 weeks after treatment. Conclusions Aerosol Aza aerodynamic size favors deposition of the drug to the human lower airways. The aerosol process do not compromise the drug activity. Aerosolized Aza has higher lung deposition and much less systemic toxicity than IV drug. The safe starting dose for clinical phase I trials should be 2.5 mg/m2 for 5 to 7 days.

AB - Background Azacitidine as an effective epigenetic therapeutic agent has not been used as an aerosol form to treat lung cancer patients. We aerosolized clinical grade azacitidine (Aza), optimized the formulation, and studied its pharmacokinetics and toxicity in mice. Methods Extrusion-precipitation method and DNA methyltransferase inhibition rate were used to measure the aerodynamic size and aerosolized Aza activity. In the single dose pharmacokinetic study, Aza concentrations in peripheral blood and lungs were measured by LC-MS method. In the multiple-dose toxicity studies, histo-pathological evaluation was used to determine the organ and bone marrow toxicities. Results In pharmacokinetic study, aerosolized Aza was found to deposit mainly into the lung with very little drug detected in the circulation. In contrast, intravenously injected (IV) Aza resulted in a high Aza concentration in the peripheral blood, with trace amounts of drug in the lung, and it was associated with significant myelosuppression. No significant myelosuppression, pulmonary toxicity, hepatotoxicity, or nephrotoxicity were observed at a daily dose of 2.5 mg/m2 for 7 days. Reversible lung inflammation was found in mice treated with 7.5 mg/m2 aerosolized Aza at 3 but not 6 weeks after treatment. Conclusions Aerosol Aza aerodynamic size favors deposition of the drug to the human lower airways. The aerosol process do not compromise the drug activity. Aerosolized Aza has higher lung deposition and much less systemic toxicity than IV drug. The safe starting dose for clinical phase I trials should be 2.5 mg/m2 for 5 to 7 days.

KW - Circulation drug levels

KW - Demethylating agent

KW - Inhalation

KW - Lung deposition

KW - Pulmonary and bone marrow toxicities

UR - http://www.scopus.com/inward/record.url?scp=84971636085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971636085&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2015.09.005

DO - 10.1016/j.cllc.2015.09.005

M3 - Article

C2 - 26531130

AN - SCOPUS:84971636085

VL - 17

SP - 214-222e1

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 3

ER -